These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19319484)

  • 1. Simultaneous optimal experimental design on dose and sample times.
    Nyberg J; Karlsson MO; Hooker AC
    J Pharmacokinet Pharmacodyn; 2009 Apr; 36(2):125-45. PubMed ID: 19319484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
    Zhang L; Beal SL; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):387-404. PubMed ID: 15000421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of population D-optimal designs via pharmacokinetic simulations.
    Hooker AC; Foracchia M; Dodds MG; Vicini P
    Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous versus sequential optimal design for pharmacokinetic-pharmacodynamic models with FO and FOCE considerations.
    McGree JM; Eccleston JA; Duffull SB
    J Pharmacokinet Pharmacodyn; 2009 Apr; 36(2):101-23. PubMed ID: 19224348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods.
    Zhang L; Beal SL; Sheinerz LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):405-16. PubMed ID: 15000422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal population designs for PK models with serial sampling.
    Gagnon R; Leonov S
    J Biopharm Stat; 2005; 15(1):143-63. PubMed ID: 15702610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.
    Proost JH; Schiere S; Eleveld DJ; Wierda JM
    Biopharm Drug Dispos; 2007 Nov; 28(8):455-73. PubMed ID: 17847121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of robust criteria for D-optimal designs.
    Foo LK; McGree J; Eccleston J; Duffull S
    J Biopharm Stat; 2012; 22(6):1193-205. PubMed ID: 23075017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.
    Hooker A; Vicini P
    AAPS J; 2005 Nov; 7(4):E759-85. PubMed ID: 16594631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models.
    Krzyzanski W; Dmochowski J; Matsushima N; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):635-55. PubMed ID: 16941234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro simulation of in vivo pharmacokinetic model with intravenous administration via flow rate modulation.
    Chen YC; Liang W; Hu JL; He GL; Wu XJ; Liu XF; Zhang J; Hu XQ
    J Pharmacokinet Pharmacodyn; 2015 Feb; 42(1):33-43. PubMed ID: 25354895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating dose equivalence for new routes of drug administration.
    Weerakkody G; Gonzales C; Muchmore D; Chien J
    J Biopharm Stat; 2004 Nov; 14(4):1021-36. PubMed ID: 15587978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models.
    Dumont C; Lestini G; Le Nagard H; Mentré F; Comets E; Nguyen TT;
    Comput Methods Programs Biomed; 2018 Mar; 156():217-229. PubMed ID: 29428073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing departure from dose linearity under a repeated measures incomplete block design.
    Cheng B; Chow SC
    Pharm Stat; 2011; 10(4):357-62. PubMed ID: 21104786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.
    Ince I; de Wildt SN; Tibboel D; Danhof M; Knibbe CA
    Drug Discov Today; 2009 Mar; 14(5-6):316-20. PubMed ID: 19059496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of covariance between random effects in design for nonlinear mixed-effect models with an illustration in pediatric pharmacokinetics.
    Dumont C; Chenel M; Mentré F
    J Biopharm Stat; 2014; 24(3):471-92. PubMed ID: 24697342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some considerations on the design of population pharmacokinetic studies.
    Duffull S; Waterhouse T; Eccleston J
    J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):441-57. PubMed ID: 16284917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic-pharmacodynamic model for educational simulations.
    van Meurs WL; Nikkelen E; Good ML
    IEEE Trans Biomed Eng; 1998 May; 45(5):582-90. PubMed ID: 9581056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simulation for clinical repeated-dose pharmacokinetic trials applying a peak-and-trough sampling design to estimate oral clearance.
    Ishida K; Kayano Y; Taguchi M; Hashimoto Y
    Biol Pharm Bull; 2007 Nov; 30(11):2159-62. PubMed ID: 17978492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving Improved Sampling Protocols for Dose-Response Modelling Using Genetic Algorithms with a Profile-Likelihood Metric.
    Lam NN; Murray R; Docherty PD
    Bull Math Biol; 2024 May; 86(6):70. PubMed ID: 38717656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.